As discussed above (see Section 36 and Section 37), in terms of the ACH2.0, the ACH-based AD drugs exert their potentially preventive effect (on conventional AD) by reducing the rate of accumulation of AβPP-derived iAβ or elevating the extent of the T1 threshold. This evidence concerns the gene APP and Alzheimer disease.